A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists
- PMID: 23487168
- DOI: 10.1124/pr.112.007278
A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists
Abstract
Angiotensin II type 1 receptor antagonists (ARBs) have become an important drug class in the treatment of hypertension and heart failure and the protection from diabetic nephropathy. Eight ARBs are clinically available [azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan]. Azilsartan (in some countries), candesartan, and olmesartan are orally administered as prodrugs, whereas the blocking action of some is mediated through active metabolites. On the basis of their chemical structures, ARBs use different binding pockets in the receptor, which are associated with differences in dissociation times and, in most cases, apparently insurmountable antagonism. The physicochemical differences between ARBs also manifest in different tissue penetration, including passage through the blood-brain barrier. Differences in binding mode and tissue penetration are also associated with differences in pharmacokinetic profile, particularly duration of action. Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly telmisartan, are partial agonists at peroxisome proliferator-activated receptor-γ. All of these properties are comprehensively reviewed in this article. Although there is general consensus that a continuous receptor blockade over a 24-hour period is desirable, the clinical relevance of other pharmacological differences between individual ARBs remains to be assessed.
Similar articles
-
Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.Int J Clin Pharmacol Res. 2005;25(1):41-6. Int J Clin Pharmacol Res. 2005. PMID: 15864875
-
Pharmacological properties of angiotensin II receptor antagonists.Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. Can J Cardiol. 1999. PMID: 10579749 Review.
-
Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers.Curr Pharm Des. 2013;19(17):3002-8. doi: 10.2174/1381612811319170005. Curr Pharm Des. 2013. PMID: 23176212 Review.
-
Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b.Theor Biol Med Model. 2006 Jan 10;3:1. doi: 10.1186/1742-4682-3-1. Theor Biol Med Model. 2006. PMID: 16403216 Free PMC article.
-
The place of ARBs in heart failure therapy: is aldosterone suppression the key?Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719868134. doi: 10.1177/1753944719868134. Ther Adv Cardiovasc Dis. 2019. PMID: 31401939 Free PMC article. Review.
Cited by
-
Valsartan: An Angiotensin Receptor Blocker Modulates BDNF Expression and Provides Neuroprotection Against Cerebral Ischemic Reperfusion Injury.Mol Neurobiol. 2024 May 25. doi: 10.1007/s12035-024-04237-x. Online ahead of print. Mol Neurobiol. 2024. PMID: 38789895
-
Association between types of antihypertensive medication and the risk of atrial fibrillation: a nationwide population study.Front Cardiovasc Med. 2024 May 9;11:1372505. doi: 10.3389/fcvm.2024.1372505. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38784173 Free PMC article.
-
Conversion of Olmesartan to Olmesartan Medoxomil, A Prodrug that Improves Intestinal Absorption, Confers Substrate Recognition by OATP2B1.Pharm Res. 2024 May;41(5):849-861. doi: 10.1007/s11095-024-03687-1. Epub 2024 Mar 14. Pharm Res. 2024. PMID: 38485855
-
Sex-related similarities and differences in responses to heart failure therapies.Nat Rev Cardiol. 2024 Jul;21(7):498-516. doi: 10.1038/s41569-024-00996-1. Epub 2024 Mar 8. Nat Rev Cardiol. 2024. PMID: 38459252 Review.
-
Effects of Angiotensin Receptor Blockers on Streptozotocin-Induced Diabetic Cataracts.J Clin Med. 2023 Oct 19;12(20):6627. doi: 10.3390/jcm12206627. J Clin Med. 2023. PMID: 37892765 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases